An 8-yr-old nonallergic girl with non-Hodgkin's lymphoma had markedly elevated serum IgE at presentation (>10,000 IU/ml), negative skin tests to a battery of 24 common allergens, and no evidence of parasitic infestation. Serum levels of IgG, IgA, and IgM were normal. Remission after cytotoxic chemotherapy was accompanied by a marked reduction in serum IgE levels (to <200 IU/ml) with no change in the level of serum IgG, IgM, or 
Introduction
Substantial evidence in experimental animals indicates that IgE synthesis is under the control of regulatory T cells (1, 2 IgE specific helper T cells have been described in the rat by Ishizaka and co-workers (3, 4) . They appear to bear Fc receptors for IgE (FcR)' and to secrete glycoproteins that bind to IgE, i.e., IgE binding factors. Functional studies indicate that highly glycosylated IgE binding factors potentiate IgE synthesis in an isotype specific manner. We have recently derived FcR positive T cell lines from the blood of patients with the hyper-IgE syndrome and we have shown that these lines secrete into their supernatants a factor(s) that provides IgE specific help (5). This factor binds to IgE, is glycoprotein in nature, and acts on IgE bearing B cells.
In this study we describe a patient with a non-Hodgkin's lymphoma and extremely elevated serum IgE. The serum IgE in this patient returned to the normal range with the regression of the tumor only to rise again when the tumor recurred. Cell surface analysis of the tumor cells revealed them to be T3+, T4+ , and T8+ and to bear FcR. The tumor cells released into their culture supernatants an IgE specific enhancing factor that had affinity for IgE. The patient's tumor may represent a malignant proliferation of a subpopulation of IgE specific helper T cells.
Case report. An 8-yr-old female was admitted to the King Faisal Hospital, Riyadh, Saudi Arabia, with a 3-mo history of chest pain, cough, and shortness of breath. Physical examination revealed a thin child, 28 kg in weight, 129 cm in height, with a bulging left hemithorax, absent breath sounds over the left chest field, and decreased breath sounds over the right chest field. Cervical, axillary, and left inguinal lymph nodes were moderately enlarged. The liver and spleen edges were each 5 cm below the costal margin. Chest x-ray revealed a completely opaque left hemithorax and a mediastinal shift to the right. Computerized axial tomography scan revealed a solid tumor filling the left hemithorax. Pleural fluid from the left chest revealed no malignant cells but abundant eosinophils and few lymphocytes. Histologic examination of the chest mass biopsy revealed cells with irregular nuclei, most of which were convoluted; scanty cytoplasm, and undifferentiated and inconspicuous nucleoli. There were occasional plasma cells and a small number of eosinophils. Fig. 1 shows an electron micrograph of the tumor, which illustrates the irregular convoluted nuclei observed in the majority of the tumor cells and a high nuclear to cytoplasmic ratio. There was a lack of intercellular junctions, of neurosecretory granules, and of cytoplasmic filaments.
On admission, the leukocyte count was 11,400 cells/mm3 Examination of Fig. 2 Analysis of surface markers. T cell surface markers of the tumor cells were analyzed by indirect immunofluorescence using the monoclonal antibodies OKT3, OKT4, and OKT8 (Ortho Diagnostic Systems, Inc., Raritan, NJ), control mouse ascites, and fluorescein conjugated F(ab')2 goat anti-mouse Ig (Tago Inc., Burlingame, CA) as described previously (7) . The percent of cells bearing surface Igs was determined by direct immunofluorescence using fluorescein conjugated polyvalent goat anti-human Igs (Cappel Laboratories, Cochranville, PA). Background staining was always <2% and was subtracted from the experimental values.
Fluorescence was read under a fluorescent microscope (Carl Zeiss, Inc., Thornwood, NY) with epi-illumination by two individuals who had no knowledge of the contents of the samples. The average of the two readings was taken. The two readings were always in close agreement with each other.
Analysis of Fc receptors for IgE. Tumor cells were incubated at 5 X 106/ml in RPMI 1640 10% FCS and 0.1% sodium azide with a solution of 10 ug/ml of human myeloma IgE or with a solution of 10 ,ug/ml of human IgG. This IgG was a Cohn's Fraction II (Massachusetts Biologicals, Jamaica Plain, MA) purified further over DEAE. After incubation for 45 min on ice, the cells were washed three times in the above medium. The cells were resuspended to the original volume and incubated with a 1:10 dilution of a 10-25 1Ag/ml of fluorescein conjugated goat anti-human IgE. This antiserum was obtained by immunizing a goat with human IgE, isolating the IgG fraction of the antiserum, and absorbing it with human IgM, IgG, IgA, myelomas, and K and L Bence Jones proteins followed by immunosorbent purification over a column of IgE myeloma. The goat anti-human IgE was then fluorescein conjugated according to the procedure described in (8) . After 45 min at 40C the cells were washed three times and fluorescence was determined as described above. Background fluorescence of cells preincubated with IgG was <2% and was subtracted from the experimental value.
Assay for the secretion of helper factors by tumor cells. Cells were incubated at 5 X 106 cells/ml in RPMI 1640-10% FCS for 48 h at 370C. Culture supernatants were collected and then passed through a CF50-A Centriflo membrane (Amicon Corp., Danvers, MA) with a molecular weight cutoff of 50,000 D. The filtrate was sterilized by passage through a 0.45-,gm millipore filter and was frozen at -20°C until tested.
Induction ofIgE synthesis in B cells. Tumor cell supernatants were assessed for their capacity to enhance IgE synthesis by cultures of B cells obtained from four subjects with allergic rhinitis whose serum IgE levels ranged from 200 to 400 IU/ml, respectively, and on B cells from two normal subjects (serum IgE of <10 IU/ml).
The Determination of IgG. IgG in culture supernatants was measured by a solid-phase competitive RIA as previously described (10 Fig. 3 shows that the tumor B cell supernatants selectively enhanced IgE synthesis in the B cells of four allergic subjects studied. The preformed IgE in acid treated cell pellets was equivalent in B cells to which medium or T lymphoma supernatants were added. The mean total IgE present in 7-d cultures of B cells that received T lymphoma supernatants (2,450±650 pg/ml) was significantly higher (P < 0.01) than the mean total IgE present in B cells cultured with medium alone (930±320 pg/ml). In contrast, T lymphoma supernatants did not enhance IgG synthesis in the B cells from the allergic subjects (Fig. 3) .
The effect of T lymphoma supernatants was studied on B cells from normal subjects. These cells contained no detectable preformed IgG (<200 pg/ml) and failed to synthesize any detectable IgE regardless of the presence or absence of added (Fig. 4) .
Discussion
This study documents the capacity of a human T cell lymphoma to secrete IgE isotype specific enhancing factor(s). These factor(s), like those secreted by T cells from parasite infested rats (3, 4) and by T cells of patients with the hyper-IgE syndrome (5), had affinity for IgE. The occurrence of extremely elevated serum IgE levels in a patient with non-Hodgkin's lymphoma who was nonatopic and had no family history of allergic disease brought up the intriguing possibility that these two findings were interrelated. This was strengthened by the observation that during tumor remission induced by cytotoxic drugs, serum IgE levels dropped dramatically, whereas relapse of the lymphoma was associated with a marked rise in serum IgE levels ( Fig. 2) but with no changes in serum levels of other isotypes. The increased serum IgE was not due to a monoclonal proliferation of IgE B Cells because isoelectric focusing of serum IgE revealed a polyclonal pattern.
The morphology of the patient's tumor cells, in particular the presence of convoluted nuclei (Fig. 1) , was suggestive of T cells. The T cell nature of these cells was confirmed by phenotypic analysis of tumor cells obtained during the relapse. This showed 98% of cells to be T3+, T4+, and T8+ (Table  I) . This phenotype is thought to be charascteristic of immature thymocytes (stage III thymocytes), which have not yet differentiated along either the T4 or the T8 pathway, despite acquiring the T3 antigen, which is specific for T cells (1 1). In this regard, circulating T cells coexpressing the T3, T4, T8, and T10 surface antigens have been reported to occur in some patients with severe combined immunodeficiency syndrome (12) . In these patients a block in T cell maturation and differentiation could have resulted in the appearance of immature T cells in the periphery.
Since T cells are known to play an important role in the potentiation of IgE synthesis, we further investigated the functional activity of soluble factors secreted by this patient's lymphoma cells. These studies revealed that her T cell lymphoma produced factors that enhanced IgE synthesis by B cells from patients with allergic rhinitis but not by B cells from normal donors (Table II, Fig. 3 ). This enhancement was isotype specific because no changes were observed in IgG synthesis by the same B cell cultures after addition of lymphoma supernatants. Characterization of the IgE potentiating factor revealed that it could bind to immobilized IgE but not to immobilized IgG and was, thus, an IgE binding factor (Fig.  4) . The If the T3+, T4+, T8+, FcR+ lymphoma currently studied represents the monoclonal expansion of a normally occurring IgE specific human helper T cell subpopulation, it would suggest that the T4 or T8 surface markers may not be necessarily indicative of IgE helper vs. suppressor function. Recent studies on human T cell clones have suggested that the T4 and T8 surface antigen play an important role in the recognition of HLA-DR and HLA-A,B histocompatibility antigens rather than imparting helper or suppressor/cytotoxic T cell function (19) (20) (21) (22) . Further studies are in progress to delineate the heterogeneity of human T cell subpopulations that play a role in regulating IgE synthesis in human.
